CPDR Updates Its Prostate Cancer Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

ROCKVILLE, Maryland-The website for the Center for Prostate Disease Research (CPDR) has a whole new look. Stephen Doyle, an experienced graphic artist, has updated and redesigned the site to be a user-friendly tool for patients, clinicians, scientists, and the general public to find information about prostate cancer and related diseases.

ROCKVILLE, Maryland—The website for the Center for Prostate Disease Research (CPDR) has a whole new look. Stephen Doyle, an experienced graphic artist, has updated and redesigned the site to be a user-friendly tool for patients, clinicians, scientists, and the general public to find information about prostate cancer and related diseases.

CPDR director Judd W. Moul, MD, a colonel in the Army Medical Department, commented, "Previously, the content was sound, but there was not as much in terms of presentation. Now, my patients say that it has great readability and visual appeal." To visit the CPDR website, go to www.cpdr.org. 

Articles in this issue
Elderly Colon Cancer Patients Benefit From Adjuvant Chemotherapy
Stromal Cells May Be Involved in Development of Breast Carcinoma
Intercultural Facts About Cancer
Nurse-Provided Education Crucial to Sural Nerve Graft Prostatectomy Patients
18-Gene Cluster Found in ER-Positive Breast Cancers
Viread OK’d for Treating HIV With Other Antiretrovirals
Surgeons in New York Operate on Patient in France
Fulvestrant Reduces Cell Turnover Index More Than Tamoxifen
New Lung Cancer Campaign Launched
CPDR Updates Its Prostate Cancer Website
NIAID Begins Phase I Trial of a DNA-Based HIV Vaccine
PET Used to Measure Efficacy of an Angiogenesis Inhibitor
Avon Donates $20 Million to NCI for Cancer Research
Weekly Gemcitabine/Vinorelbine Proves Effective in NSCLC
Supplemental NDA Submitted for Gleevec

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
4 experts in this video
4 experts in this video
Related Content
The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

PROSTOX Ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore
April 9th 2025
Article

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Tim Cortese
March 26th 2025
Article

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

FDA Approves PET Imaging Agent for Prostate Cancer

FDA Approves PET Imaging Agent for Prostate Cancer

Ariana Pelosci
March 21st 2025
Article

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

A World of Research, Care, and Science: Becoming A Radiation Oncologist

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Tim Cortese
March 12th 2025
Article

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.